An interventional study of Bariatric surgery in Obesity, Morbid and Insulin Resistance, sponsored by Turku University Hospital. Status unknown at 1 site in Finland. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-15.
Sponsored by Turku University Hospital · Not applicable, Interventional, and Treatment
Background: Morbid obesity is associated with decreased brain µ-opioid receptor availability, possibly resulting in higher food intake needed to gain pleasure from eating. This decrease seems to normalize already 6 months after bariatric surgery, but the longer-term effects have not been studied. Obesity and insulin resistance result in significantly increased brain insulin-stimulated glucose uptake, whereas in every other tissue glucose uptake is lower. One possible explanation to this could be central inflammation and activation of brain glial cells, which has been shown to occur in animal models of obesity. Obesity has also been shown to associate with increased risk of Alzheimer's disease and cognitive decline in several studies.
Aims: The first objective of this study is to both study the effects of bariatric surgery as well as compare the effects of gastric bypass and sleeve gastrectomy on food-associated pleasure, extending the follow-up period to 2 years postoperatively. The second aim is to investigate the effect of morbid obesity and weight loss on brain inflammation and gliosis and its association with increased brain insulin-stimulated glucose uptake. Furthermore, association of obesity, insulin resistance, central inflammation and neurocognitive dysfunction are evaluated.
Methods: A total of 60 morbidly obese subjects, 30 assigned for Roux-en-Y gastric bypass and 30 for sleeve gastrectomy according to routine treatment protocols will be recruited for this study. A control group of 30 healthy subjects will also be recruited. We will perform 1) structural MRI and MRS, 2) functional MRI during tasting and visual food cues, 3) PET imaging of µ-opioid receptor availability using [11C]-carfentanil, 4) PET imaging of cerebral inflammation and astrocyte activation using [11C]-PK11195, 5) measurement of whole-body and tissue insulin sensitivity by combining hyperinsulinemic, euglycemic clamp with [18F]-FDG-PET, 6) neuropsychological testing. The control group will only be studied once, whereas study procedures will be repeated for the morbidly obese before very-low calorie diet and 6, 12 and 24 months postoperatively.
Morbidly obese group
Non-obese controls
Exclusion criteria:
Morbidly obese group
Non-obese controls
Bariatric surgery (Roux-en-Y gastric bypass or sleeve gastrectomy)
Procedure: Bariatric surgery
Non-obese controls are only studied at baseline
Roux-en-Y gastric bypass or sleeve gastrectomy, chosen based on routine evaluation process
Also known as: Roux-en-Y gastric bypass, Sleeve gastrectomy
Change in central inflammation
Assessment of brain glial cell activation using \[11C\]-PK11195 tracer and positron emission tomography
Time frame: Controls: 0 months; Morbidly obese: preoperatively, 6 months postoperatively
Changes in central reward system using fMRI imaging
Assessment of brain reward system activation after visual/taste cues using functional MRI
Time frame: Controls: 0 months; Morbidly obese: preoperatively, 6 months, 12 months, 24 months postoperatively
Changes in brain μ-opioid receptor availability using PET imaging
Assessment of brain μ-opioid receptor availability using \[11C\]-carfentanil tracer and positron emission tomography
Time frame: Controls: 0 months; Morbidly obese: preoperatively, 6 months, 12 months postoperatively
Changes in cognitive function studied with testing
Neuropsychological testing focusing on memory, decision-making and inhibition
Time frame: Controls: 0 months; Morbidly obese: preoperatively, 6 months, 12 months, 24 months postoperatively
Changes in whole-body insulin sensitivity usign FDG-PET imaging
Assessment of whole-body insulin sensitivity using hyperinsulinemic, euglycemic clamp
Time frame: Controls: 0 months; Morbidly obese: preoperatively, 6 months postoperatively
Changes in tissue-specific insulin sensitivity using FDG-PET imaging
Assessment of insulin-stimulated glucose uptake in the brain, liver, skeletal muscle and adipose tissue by performing positron emission tomography with \[18F\]-fluorodeoxyglucose tracer during hyperinsulinemic, euglycemic clamp
Time frame: Controls: 0 months; Morbidly obese: preoperatively
Plan to share: Yes — Under preparation.
Supporting information: Study protocol, Sap, Icf, Csr
No publications or documents are linked to this record.
This study is status unknown, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Infectious Encephalitis
Turku University Hospital